Auswahl aktuell laufender klinischer Pharma-Studien am NCRC
| Titel |
Link zum öffentlichen Register-Eintrag |
Rekrutierungs- status |
| A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES) |
NCT04411641 | beendet |
| A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) |
NCT04458051 | aktiv |
|
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab as monotherapy or in addition to baseline therapy in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) |
NCT05271409 | aktiv |
|
A Randomized, double-blind, Placebo-controlled, multicenter Phase 3 pivotal study to evaluate the efficacy and safety of rozanolixizumab to treat adult patients with Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease (MOG-AD) |
NCT05063162 | aktiv |
| Titel |
Link zum öffentlichen Register-Eintrag |
Rekrutierungs- status |
| Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis |
NCT05403541 | aktiv |
| Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis (ADAPTSC+) |
NCT04818671 | aktiv |
| A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis |
NCT04951622 | aktiv |
| A Phase 3B, Randomized, Open-label, Parallel-Group Trial to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis (ADAPT NXT) |
NCT04980495 | aktiv |
| A Phase 3, multinational, randomized, double-blind, placebo-controlled trial to examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis (NIMBLE) |
aktiv | |
| Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | aktiv |
| Titel |
Link zum öffentlichen Register-Eintrag |
Rekrutierungs- status |
| To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP |
NCT05581199 | aktiv |